<SEC-DOCUMENT>0000950170-25-038703.txt : 20250313
<SEC-HEADER>0000950170-25-038703.hdr.sgml : 20250313
<ACCEPTANCE-DATETIME>20250313160340
ACCESSION NUMBER:		0000950170-25-038703
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20250313
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250313
DATE AS OF CHANGE:		20250313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			aTYR PHARMA INC
		CENTRAL INDEX KEY:			0001339970
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				203435077
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37378
		FILM NUMBER:		25735669

	BUSINESS ADDRESS:	
		STREET 1:		10240 SORRENTO VALLEY ROAD
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8587318389

	MAIL ADDRESS:	
		STREET 1:		10240 SORRENTO VALLEY ROAD
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>atyr-20240314.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-13T13:47:12.4789+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:atyr="http://www.atyrpharma.com/20240314" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_18f02ab1-44b4-4d9c-b700-c4f5816de3be" name="dei:EntityCentralIndexKey" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd">0001339970</ix:nonNumeric><ix:nonNumeric id="F_cb6f9cc1-f635-4b80-b71c-7e321233f48e" name="dei:AmendmentFlag" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="atyr-20240314.xsd"/></ix:references><ix:resources><xbrli:context id="C_85e8cb65-225c-451c-96f5-48835f1991fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001339970</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-14</xbrli:startDate><xbrli:endDate>2024-03-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80a76908-b053-40eb-ace4-2fd9228e3819" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9b91d4a-fd8c-488e-958f-f1bfbd47b7e0" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 13, 2025</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f11d1dfc-67e8-4ed6-9402-78c0cabfa3bd" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATYR PHARMA, INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:36.28%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:27.12%;box-sizing:content-box;"/>
    <td style="width:5.96%;box-sizing:content-box;"/>
    <td style="width:29.64%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b23ff7ec-effb-46ad-bd32-ccdd9b2b6cb0" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a31dd039-1579-4caa-8745-52a27226a3cc" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-37378</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a0779f50-7f3d-48f6-bcfa-73827474b6d9" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">20-3435077</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">of incorporation)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(Commission</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">File Number)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_266de1f9-5da6-4988-80f0-f15b2bdb148c" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10240 Sorrento Valley Road</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_ce6b6252-e449-4b94-9b25-19be12a37acc" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 300</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3f12a541-ca9c-420f-99ce-7ea022460bad" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">San Diego</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_31b507f2-94df-4dce-822c-27465d99e957" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">CA</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_591dfbc2-ee1a-4c17-9ac2-68f155680529" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92121</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_22fe71cf-65d9-463b-bd09-f42016ee8cd1" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">858)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bbe6081d-a974-4aba-b06b-d29ab7fd60cb" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">731-8389</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not Applicable</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:4.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_c1316685-015d-4693-b00f-dac067e23a77" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:4.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_aa358c58-6de2-47e0-9cc4-758b1124a6b2" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:4.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_154d649a-8ff5-4b12-b1f5-f8bb3b6843a6" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:4.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_0c3b8edf-4f69-4404-90ac-22ca0775c84f" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:35.267%;box-sizing:content-box;"/>
    <td style="width:26.205%;box-sizing:content-box;"/>
    <td style="width:38.528%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b641dc9b-63fe-4df2-9146-09b7c186637c" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ATYR</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The </span><span><ix:nonNumeric id="F_61e55019-3cca-4db1-8e2d-4b2afa67538c" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nasdaq</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Capital Market</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company     </span><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_8831e936-566f-4f6f-a94d-08f7334d4d6d" contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02  Results of Operations and Financial Condition.</span></p>
  <p style="margin-left:9.347%;text-indent:-19.997%;padding-left:15.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:7.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 13, 2025, aTyr Pharma, Inc. issued a press release announcing financial results for the year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.</span></p>
  <p style="text-indent:7.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:7.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information under this Item 2.02, including Exhibit 99.1 hereto is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01	Financial Statements and Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)  Exhibits</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:16.08%;box-sizing:content-box;"/>
    <td style="width:3.34%;box-sizing:content-box;"/>
    <td style="width:80.58%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;text-align:left;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="atyr-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release, dated March 13, 2025</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10.5pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10.5pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10.5pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:19.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt solid;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:13.2pt;font-family:Times New Roman;margin-bottom:1.1pt;border-bottom:0.75pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURE</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.26%;box-sizing:content-box;"/>
    <td style="width:4.32%;box-sizing:content-box;"/>
    <td style="width:45.42%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ATYR PHARMA, INC.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jill M. Broadfoot</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jill M. Broadfoot</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 13, 2025</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt solid;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>atyr-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img137952089_0.jpg" alt="img137952089_0.jpg" style="width:123px;height:68px;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:70%;box-sizing:content-box;"></td>
    <td style="width:30%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">IMMEDIATE RELEASE</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">Contact:</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#222222;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Ashlee Dunston</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#222222;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Sr. Director, Investor Relations and Public Affairs</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">              </font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#1155cc;white-space:pre-wrap;text-decoration:underline solid;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">adunston@atyrpharma.com</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">                                  </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Topline data from Phase 3 EFZO-FIT&#153; study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT&#153; study reinforces its favorable safety profile.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Publication in Science Translational Medicine validates efzofitimod&#x2019;s mechanism of action.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Company to host conference call and webcast today, March 13th at 5:00 p.m. EDT / 2:00 p.m. PDT.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">SAN DIEGO &#x2013; March 13, 2025 &#x2013; aTyr Pharma, Inc. (Nasdaq: ATYR) (&#x201c;aTyr&#x201d; or the &#x201c;Company&#x201d;), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2024 results and provided a corporate update.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;2024 was an important year for aTyr, as we completed enrollment in our global pivotal Phase 3 EFZO-FIT&#153; study, which is the largest interventional study ever to be conducted in pulmonary sarcoidosis, a disease where incidence and prevalence are rising yet there are still limited treatment options,&#x201d; said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. &#x201c;The stage is set for 2025 to be a potential milestone year as we look toward reporting topline data for EFZO-FIT&#153; in the third quarter. Leading into this pivotal readout, we are very pleased with the execution of the study to date and the continued favorable safety profile demonstrated for efzofitimod, including our most recent positive DSMB review, which recommended the study continue as designed. Efzofitimod is poised to potentially become a safe and effective alternative to the current standard of care and improve patients&#x2019; lives.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Fourth Quarter 2024 and Subsequent Period Highlights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Enrollment complete in the global pivotal Phase 3 EFZO-FIT&#153; study to evaluate the efficacy and safety of efzofitimod in patients with pulmonary sarcoidosis. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">This is a randomized, double-blind, placebo-controlled, 52-week study consisting of three parallel cohorts randomized equally to either 3.0 mg/kg or 5.0 mg/kg of efzofitimod or placebo dosed intravenously monthly for a total of 12 doses. The study enrolled 268 patients with pulmonary sarcoidosis at 85 centers in nine countries. </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The trial design incorporates a forced steroid taper. The primary endpoint of the study is steroid reduction. Secondary endpoints include measures of sarcoidosis symptoms and lung function. Topline data from the study are expected in the third quarter of 2025. Patients who complete the study and wish to receive treatment with efzofitimod outside of the clinical trial are eligible to participate in an Individual Patient Expanded Access Program.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Held a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss the statistical analysis plan (SAP) for the Phase 3 EFZO-FIT&#153; study.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> The main objective of the meeting was to finalize the way in which the study endpoints are assessed from a statistical standpoint. Based on FDA feedback, steroid reduction will be measured as the absolute change from baseline to week 48. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Announced the fourth positive data and safety monitoring board (DSMB) review for the Phase 3 EFZO-FIT&#153; study.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  The independent DSMB recommended that the study continue without modifications based on the pre-planned analysis.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Enrollment ongoing in the Phase 2 EFZO-CONNECT&#153; study to evaluate the efficacy, safety and tolerability of efzofitimod in patients with limited and diffuse systemic sclerosis (SSc, or scleroderma)-related interstitial lung disease </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">SSc-ILD). </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">This proof-of-concept study is a randomized, double-blind, placebo-controlled, 28-week study consisting of three parallel cohorts randomized 2:2:1 to either 270 mg or 450 mg of efzofitimod or placebo dosed intravenously monthly for a total of six doses. The study</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">intends to enroll up to 25 patients at multiple centers in the United States.</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Patients who complete the study are eligible to participate in a 24-week open-label extension. Interim data from the study are expected in the second quarter of 2025 and will focus on skin assessments measured at baseline and week 12 in approximately 8 patients, including patients on drug and placebo. The data will include skin histopathology, including immune biomarkers, and the modified Rodnan skin score. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Manuscript demonstrating the immunomodulatory activity for efzofitimod in lung inflammation and fibrosis published in the peer-reviewed journal </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Science Translational Medicine</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> The publication describes efzofitimod&#x2019;s unique anti-inflammatory effect on macrophages through neuropiln-2 (NRP2) and details the preclinical data supporting its development. The publication, which is entitled, &#x201c;A human histidyl-tRNA synthetase splice variant therapeutic targets NRP2 to resolve lung inflammation and fibrosis,&#x201d; is available on the journal&#x2019;s website and at: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">https://www.science.org/doi/10.1126/scitranslmed.adp4754</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Posters for efzofitimod accepted for presentation at the upcoming American Thoracic Society (ATS) 2025 International Conference.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> The conference is scheduled to take place May 16 &#x2013; 21, 2025, in San Francisco, CA.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Poster 9320 &#x2013; Real-World Treatment Patterns Among Pulmonary Sarcoidosis Patients with Parenchymal Involvement in the US on Sunday May 18, 2025, at 11:30 a.m. PDT.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Poster 6808 &#x2013; EFZO-FIT, Largest Placebo-Controlled Trial in Pulmonary Sarcoidosis &#x2013; Trial Design and Patient Characteristics</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">on Monday, May 19, 2025, at 11:30 a.m. PDT.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Poster 9092 &#x2013; Incidence, Prevalence, and Mortality of Pulmonary Sarcoidosis with Parenchymal Involvement in the US on Tuesday May 20, 2025, at 11:30 a.m. PDT.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Presented preclinical research demonstrating anti-fibrotic effects of ATYR0101 in lung and kidney fibrosis in two posters at the Keystone Symposia on Fibrosis: Inflammation, Drivers, and Therapeutic Resolution. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The findings demonstrated that ATYR0101 interacts with LTBP-1 to induce myofibroblast apoptosis through a novel anti-fibrotic mechanism and suggest that ATYR0101 has the potential to be a next generation anti-fibrotic drug for lung and kidney fibrosis.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Appointed Eric Benevich to the Company&#x2019;s Board of Directors. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Mr.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Benevich currently serves as Chief Commercial Officer at Neurocrine Biosciences, Inc., where he</font><font style="color:#222222;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> is responsible for all aspects of commercial development, marketing, and sales of the Neurocrine product portfolio.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Year Ended 2024 Financial Highlights and Cash Position</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Cash &amp; Investment Position:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> Cash, cash equivalents, restricted cash and available-for-sale investments as of December 31, 2024, were $75.1 million. Subsequent to the end of the fourth quarter 2024, the Company raised approximately $18.8 million in gross proceeds from its at-the-market (ATM) offering with Jefferies LLC.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Financial Guidance: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The Company updated its prior guidance and believes its cash runway will be sufficient to fund its operations for a period of one year following the Phase 3 EFZO-FIT&#153; readout, which includes the potential filing of a Biologics License Application (BLA) for efzofitimod in pulmonary sarcoidosis.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">R&amp;D Expenses:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> Research and development expenses were $54.4 million for the year ended 2024, which consisted primarily of clinical trial costs for the Phase 3 EFZO-FIT&#153; and Phase 2 EFZO-CONNECT&#153; studies, manufacturing costs for the efzofitimod program and research and development costs for the efzofitimod and discovery programs.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">G&amp;A Expenses:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> General and administrative expenses were $13.8 million for the year ended 2024.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Collaboration and License Revenue: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Collaboration and license revenue related to the Kyorin Agreement was $0.2 million for the year ended 2024, which consisted of drug product material sold to Kyorin for the Japan portion of the EFZO-FIT&#153; study.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Conference Call and Webcast Details</font></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">aTyr will host a conference call and webcast today at 5:00 p.m. EDT / 2:00 p.m. PDT to discuss its financial results and provide a corporate update. Interested parties may access the call by registering </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">here</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> in order to</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">obtain a dial in, personalized passcode and webcast information. Links to a live audio webcast and replay may be accessed on the aTyr website Events page at: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">http://investors.atyrpharma.com/events-and-webcasts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. An audio replay will be available for at least 90 days following the event.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">About Efzofitimod</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Efzofitimod is a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis. aTyr is currently investigating efzofitimod in the global Phase 3 EFZO-FIT&#153; study in patients with pulmonary sarcoidosis, a major form of ILD, and in the Phase 2 EFZO-CONNECT&#153; study in patients with systemic sclerosis (SSc, or scleroderma)-related ILD. These forms of ILD have limited therapeutic options and there is a need for safer and more effective, disease-modifying treatments that improve outcomes.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">       </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">About aTyr</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr&#x2019;s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr&#x2019;s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">www.atyrpharma.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as &#x201c;aims&#x201d; &#x201c;anticipates,&#x201d; &#x201c;believes,&#x201d; &#x201c;can,&#x201d; &#x201c;designed,&#x201d; &#x201c;expects,&#x201d; &#x201c;intends,&#x201d; &#x201c;look toward,&#x201d; &#x201c;may,&#x201d; &#x201c;plans,&#x201d; &#x201c;potential,&#x201d; &#x201c;project,&#x201d; &#x201c;will,&#x201d; and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, among others, statements regarding interactions with the FDA relating to the SAP for the Phase 3 EFZO-FIT&#153; study, including the measurement of steroid reduction; the expected size of, and number of patients to be enrolled in, the EFZO-CONNECT&#153; study; the skin assessments and expected number of patients to be included in the interim data for the EFZO-CONNECT&#153; study; the potential therapeutic benefits and applications of efzofitimod; expectations regarding our financial guidance and the sufficiency of our cash runway; and timelines and plans with respect to certain development activities and development goals, including the potential filing of a BLA for</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">efzofitimod in pulmonary sarcoidosis and our expectation that our Phase 3 EFZO-FIT&#153; study of efzofitimod in patients with pulmonary sarcoidosis will report topline data in the third quarter of 2025 and expectation that our Phase 2 EFZO-CONNECT&#153; study will report interim data in the second quarter of 2025. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations, strategies or prospects will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks related to our reliance on third-party partners and the potential that such partners may not perform as anticipated, the fact that NRP2 and tRNA synthetase biology is not fully understood, uncertainty regarding the ultimate long-term impact of evolving macroeconomic and geopolitical conditions, the risk of delays in our clinical trials, risks associated with the discovery, development and regulation of our product candidates, including the uncertainty of related costs and regulatory filings and the risk that results from clinical trials or other studies may not support further development, the risk that we may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons, the fact that our collaboration agreements are subject to early termination, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.13%;box-sizing:content-box;"></td>
    <td style="width:1.221%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:9.247%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:1.221%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:9.247%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:1.221%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:9.247%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:1.221%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:9.247%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="16" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">ATYR PHARMA INC.</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="16" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Operations</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="16" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share data)</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">Three Months Ended</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">Years Ended</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">December 31,</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">December 31,</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">2024</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">2023</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">2024</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">2023</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Revenues:</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:14pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:2.587%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">License and collaboration agreement revenues</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">235</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">353</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Total revenues</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">235</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">353</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Operating expenses:</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:14pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:2.587%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Research and development</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">12,228</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">12,755</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">54,372</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">42,293</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:14pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:2.587%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">General and administrative</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">3,592</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">3,204</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">13,777</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">12,979</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Total operating expenses</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">15,820</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">15,959</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">68,149</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">55,272</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Loss from operations</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(15,820</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(15,959</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(67,914</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(54,919</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:14pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:2.587%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Total other income (expense), net</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">852</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1,198</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">3,892</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">4,522</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Consolidated net loss</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(14,968</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(14,761</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(64,022</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(50,397</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:14pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:2.587%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Net (gain) loss attributable to noncontrolling interest in Pangu BioPharma Limited</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(1</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">8</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Net loss attributable to aTyr Pharma, Inc.</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(14,967</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(14,760</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(64,023</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(50,389</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(0.18</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(0.25</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(0.86</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(0.94</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Shares used in computing net loss per share, basic and diluted</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">82,724,659</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">59,261,219</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">74,261,265</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">53,606,488</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.76%;box-sizing:content-box;"></td>
    <td style="width:1.64%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:12.98%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:1.64%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:12.98%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="8" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">ATYR PHARMA INC.</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="8" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">Condensed Consolidated Balance Sheets</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="8" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(in thousands)</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">December 31,</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">December 31,</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">2024</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">2023</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Cash, cash equivalents, restricted cash and available-for-sale investments</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">75,076</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">101,650</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Other receivables</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1,736</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">2,436</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Property and equipment, net</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">4,850</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">5,531</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Operating lease, right-of-use assets</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">5,817</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">6,727</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Financing lease, right-of-use assets</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1,192</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1,788</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Prepaid expenses and other assets</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">8,159</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">2,521</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:14pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:2.587%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Total assets</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">96,830</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">120,653</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Accounts payable and accrued expenses</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">13,715</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">15,088</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Current portion of operating lease liability</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">711</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">831</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Current portion of financing lease liability</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">541</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">497</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Long-term operating lease liability, net of current portion</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">11,144</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">12,339</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Long-term financing lease liability, net of current portion</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">887</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1,428</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Total stockholders&#x2019; equity</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">69,832</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">90,470</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:14pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:2.587%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#x2019; equity</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">96,830</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">120,653</font></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img137952089_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img137952089_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $5 ?$# 2(  A$! Q$!_\0
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MC9W=Y>7,I"I;6UM!)--<NQX5((T:1FZ!023@"OX3OC;X\N/BE\6OB/\ $:[
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M_F>9W"CG@=#V]A6-<J &X'W6_P#017Z*O_P2\_;\<$?\,M?$;<00#Y6GCDC
M_P"7['IU&*S)_P#@EG_P4!((_P"&6_B/D@C_ %6FYR?^WS'3V.?3BO667Y@K
M?[#C;73M]4Q"[/K3M][[=T<M6G.5FH-))WNK=O\ AE]W0_-^XZGZ'^0K(G4'
ML."/;L?2OT@F_P""5?\ P4#;./V6OB2/<PZ;SGC_ )_ ?_':RYO^"4O_  4(
M/_-K/Q-Z]K?2^<?6[/\ ]?/:NVA@\8E)2P>*BW9KGP]6&]MN>,;^=KVNEU1Q
MSIRE;EI2>G2*[+SZ[_B?FY.JG' [>WKZ5T7PQ\63>!/B5X%\;6EP]I)X9\;^
M%O$HF@)C:VM].U2SNYLD%0'9(GMR>Z97(&17WA-_P2@_X*&MC'[*OQ*/TM],
M[9[?VG[_ .>WVE^Q3_P0I_:E^(_Q0\->)/VC?"*_!CX1Z%JFF:SK-AKNI:'<
M^,O%,%AJ(>YT;2]"T.^UZ?3FFN8KA+R?7UL(Y;&:&2P,!;(]#"8#&U<12A'#
M5HRYXRBYP<8KEW]YZ)VM;;1;Z'GK"8BI**C"2?=W5GI9W2;5M[Z6\WM_;-X)
MU]?%7@SPCXH3A/$GAC0=?08 ^76-*M-17@<#BY' X':NGK/TC2[+1-)TS1=,
M@2UTW2-.LM+T^VCW&.WLK"VBM+2!"[.^R&"*.-=[,VU1N9CDG0K]5BFHQ3W2
M2?K;4^JC?E5][*_K;4****8PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"< GT!/Y5F7&HP
MVL<DES.MO'&KR/+,8XDB1,L6FEDQ$B8&59B/EY8@\B9244V[VBG*5K>[%?:>
MMU'N]EU!)MI)-N3LDE=M]DE=M_(U*I/<@  ,"6)&Y>=AP/O_ +LB(J/FQ(/K
MZ#XM^,G[<GPN^&JW>FZ!>+XV\3P!@^FZ24>RM9%)4BYU)FC@4*1GY#*2 >0"
M"/RE^)W[;/QY^(=U=Q+XC7PKH<H/V33/"\/]FQ,N!A;J_P O?7''03W+A>@&
M *_$.,_I < \(U:F!I8RKQ#FM.3I/ Y+[*M3I8A./[K%9C.7U/#N%_WD4Z\D
MGK%=?M<FX!S_ #BFL1[#ZA@VTOK.+4H.2NM:5-0FYJU]7RK:U[W7[]^)?B1X
M(\&0^9XM\:^%?#*D J^OZ]IFF2'.""(+J6!F!'3 /KSBO"M6_;=_9AT3>M]\
M8- +H67_ $+3O$&JABI*EDDT?2-1C="1\C)N5AA@64[J_FQU*ZNKZ;[1?7-Q
M>7'>:ZFDN)<\\[Y68Y]ZP[D;E*DDKP2F?E))8$D="2 ,GO\ 3BOQ7%_2DSZO
M.?\ 9O#.582FK-?7L7F&/JZM+7ZO7RVDDF]E"5[]+7?VT/"W T:;GB\TQ5:;
MMIAZ5&C&-K7:YU4YKMV2M&UNM]/Z1(O^"@W[*\A*O\2I;8#(6>?PIXJ\B902
M/-3;HHEV.!N3S(HGVD;XT;*#T+PQ^UY^SEXN:*'2OC'X*BN+C8+:+6;^3PS-
M<F0?(((?$UKI3RR-D8CA$PR0JNU?RN2PQIG:N "0!DE5&1PH)P !P !P.!69
M.% (554$G*JH",V1EV3[ID)^8OC<6R2>36F6_23XN<XO&9-P_B:4VDX489G@
MZBVUA5EF.-C=[>]1:TZHPK^'>5.*5+%XZ$W]J3P[2VUY?8M2]&UUUL?V9:9K
M-CK%K%>:9J%IJ%K*HDBN[*[M+NVGA;.V6&6T\X2(PY1@%5@#SQSLHX=0P((.
M>1[$@]?0C'UK^.SP+\:/B;\)+Q-3^'OC+7_#=X7C2,07DKZ9,ZMO\NZLY&>W
MFB8\%9(RNTD8.3C]:?V=?^"J5M>36WAO]H.P32Y))(X8/'&BVB#3UY$;?VW8
MPR,R-+/N*W-E#'%'#M\V)Y-SG]DX3\=>',]JTL-F]&KD&*J<L(U*M:&(RUS?
M)%1GB5&G6I5)SE:'/15)*ZE--QO\?FO!./P'/4PM18ZC"+E*R<*\8Z7DZ48<
MCBKI-QE>[7+&S9^UE,,:,X<@[@I0'<P^4D$C ('4#G&1V-<QX;\5:+XNT>SU
M[PWK5AK>C:BOGV.IZ;/!=VMQ!(69!')%D+,BD1S12A9(Y49'0,"*V)9W@5VD
MG \N"65E<(#L3!\YL*""OW2HPOS [2<&OVV-:E4IQJJ4)49Q52%53IU*<J;2
ME[2,Z<YQ<(Q:DY)[:JY\7).+Y7&7,I.$H<KYHR3LXRB[--/Y:;[%H[5EV@$'
M9OW;U[Y4A5W&3.%&<)M/8[BU1JN&DPB)N<L2IR9#M WN0L9#$8!!W'"CYB,
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M:J9PJO+=4<)7J+3[4Y8>$6V]K*3Y>S;[GG5$U))]K_?<ZO\ X*O?#&^^*W[
M_P"T%I>F*YU#PWX6L_B';*PW>=;?#S6-+\::I$40;V:32-&U 0HI5A>B"3)5
M/+/\"UQ'*\-Q''/&2LH:YE3+K<"V:%9"AF:5D8O/"N(W4%005/6O].;Q/X<T
M_P 4^&_$'AK6(_MVE>(=%U71-1L[@1O!<V&K6LMK=VTRA%+PS02O ZEAF%F7
M(8[Z_P UOXR_#N_^$/Q8^)7PJU;S$O?AW\0/&?@JXC. TDN@ZU?:2MQ(0JJZ
M3C21=(Z+'&ZO$Z*$(!]OC7"NCB,+C5>4:T?JTKW?(XOFAR]DHW2VM=]SFJI6
M3:VT\]6O/^OGKY!/&I..>_\ (>U9$R#WX(]/0GTK?N$ .<GH3V_P]JR)T&1R
M>>>W;CTKXZ#;N];:+7NEJ<$TETWO]]U]VG8P)T7CJ.G]?7-8LCLA) 4YB6$!
MD5@D2Y 100<D@#,C[I>!^\KHIT'')[>GO[5BSVZ8!RWYCU_W?>O0C*-2Z5W:
MU[Z;[?D>56BH\O*DOB;M_P!NK]3^[W_@@_\ %6Y^(_[ /A70[ZZ>YU+X5>,/
M%W@+:Y'GBS-S%XGL)7+.SNS?\)%=01R'8ODVXC"9C=C^TT8 1 #N 10&Z[@
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MHJR5*A2BH4TE'W?>47-];M\VI@7$?)Y['M[#WK(FC^;K^GL/>M^>,\\\X/\
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M:Y 1RV,!6)R<# !)R1T&.I]*=2'H<=<''0_H>#^/'K7UAB?Q-?\ !=CX2?\
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M');FP\%V5O:B66*V-]8!/$6IQI,=FLZK?('G15GD^(;C=EMS%NF,C&U<_(@
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M&B1R!&#1JDC'RW$2X!C<LY"NVPR+ \[9D(4R,LLNU3((Q_EX?\%M?'I^(_\
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MC:^N"[T:=4.TY86\['&X<'/U_I&#;$!0,0A5" .6"L4( [DXZ$C( YK\1/\
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M)<3R&29V8\LS2%BQ!()Z5RDJ-GIW;N/4>]?SA7Q+Q6.Q6(<E+ZSC<5B'+?\
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M6S>SZO\ (].M#XFKM\S=M^KOT,"9&P>.P[CU^M9$N8SDG!*R*0,9VA&R>/\
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MWO5(*K+1ZKWIM6\MV%%%%:GN!1110 4444 %%%% !1110 4444 07./L\N2
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M4]CZBNF$W!MI)W5M3SZFMM'V_)+Y_/Y&#,K;6X/4_P!:QIU.UN#][T]S70S
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MH>7S^A_QKHY0>1@YW9Q@].>:Q+I6XX/7T/I6,'JEW;?X?\ ^.KPMS+6SCO\
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M1O.U_A5EIW2?<P)NOXC^1K)G!XX/;L?>M^?M^']:QY^WX?UKZS!2YO9]-_\
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M@*+EI T4]QMC"DO<&V(#-&!7^@+_ ,$>OV,E_9&_94\--XDTD:=\5OBVMO\
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M;W0]*LX/(A&L>'UC\0:0Q0$;IVU33+26XN.3=SF2Y8LTS$_4T "Q1JH 4+@
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MV]/]%LYIL_@8^3CIBOXJ_'&L?\)+XO\ %7BC/_(R^(-:USO_ ,Q/4;F][_\
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M/VH*I'KT;VL[/0_/^YZ?\"'_ *":PINI^H_E7Z$R?\$U_P!M63Y3\#]1E Y
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M3OH^MG;HC\=+KJ/K_05@7/3_ ($/_037[+W'_!"/_@K#( #^R%K1 .<CXI_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRT;O;PQ>8)98H!&J*9&N7E;RPFW#$71E'$,:A<DC:1@#HYT''7M_7VK]&O\
M@EQ^R!>?M2?M$66H:W82Q_#;X5SVGBGQ;?O S6M]>0ZG&=(T6*<AHOMNJ21W
MD[1$;8+2V7S%S.CCV\NP\\=BZ&#HQE.KB*L(6BM8T]74GY*'NW=UOYGEU-D^
MB>OI=:_*WWV/Z!?^"/\ ^Q]'^SM^S^/'7B72XX/B;\7I(M7U*2:*6"\T;PM
MS)H^BJ7VO$ETT4FK7&R-&EGFM7D:3[%:>5^P2#"*-Q;"J-Q !;@?,0  ">I
M  SP .*JVMG!:006]JGV>""VBMH((P@2&&)-D*( I \E/D09*XZACS5L#  R
M3@ 9.,G QDX &3U. !Z 5_0V78&EEV$H8.@DJ=&'+LDY2=N:4K;R;6_7UNWQ
MBT445W %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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7 **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>atyr-20240314.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-13T13:47:12.6254+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.atyrpharma.com/20240314" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:atyr="http://www.atyrpharma.com/20240314" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="atyr-20240314.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46008859021344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 14, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 13,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ATYR PHARMA, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001339970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-37378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-3435077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10240 Sorrento Valley Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">731-8389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M<X!M6CE\_O)H!   NQ   !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R-
MF&%SXC80AO^*QNUT>C,DMFP(D (S#LGUF+ODN$#OINWT@[ %:&);KB2'Y-]W
M98C-7<V:+\&RO:\?K5:[JXQV4CWI+>>&O*1)IL?.UIC\VG5UM.4ITY<RYQD\
M64N5,@-#M7%UKCB+2Z,T<7W/NW)3)C)G,BKOS=5D) N3B(S/%=%%FC+U>L,3
MN1L[U'F[\2@V6V-ON)-1SC9\P<T?^5S!R*U48I'R3 N9$<778R>DUS=^UQJ4
M;WP5?*>/KHF=RDK*)SN8Q6/'LT0\X9&Q$@Q^GOF4)XE5 HY_#Z).]4UK>'S]
MIOZ^G#Q,9L4TG\KDFXC-=NP,'!+S-2L2\RAW'_AA0CVK%\E$EW_);O]NM^N0
MJ-!&I@=C($A%MO]E+P=''!O0$P;^P< ON?<?*BEOF6&3D9([HNS;H&8ORJF6
MU@ G,KLJ"Z/@J0 [,[F540%.-H1E,;G+C#"O9);M5QN\-G(-?,2^ZD8'P9N]
MH']"\)ZI2T*['>)[?O=[<Q?8*D"_ O1+O>"$WE0^<T7^#E?:*%C"?YJ(]@K=
M9@4;U]<Z9Q$?.Q"XFJMG[DQ^^8E>>;\A?$'%%V#JM0.7KSEO@L/-!Q<?$8AN
M!=%%54(@B$N*]PG;-%'@]FN6:(YP]"J.WGG.F',EI VHF$!8-OH%5]J'4= A
M-HYZ"-I5A7:%"AYB^Y%OA(TD8'Q@:2,8KA,N_WPD\P_AXWW8(;.'Z27"UJ_8
M^N>P3<%SBB6P_V+^0C[RUR8Z7,GS/!H$PV'?0[ &%=;@'*R[E*N-R#;D=[ W
M6S*5:<ZR1CA<KRW*AA77$-59\*A0P@BN21A!R(N$DX<B77'5Q(1K@;\N@G[0
M'R!<U*N3J7>.QV99)%4N59E".V1A8 L0J<!S!:PP++2,&R.O1?WV#H,\ROCT
M',@E>R&S&$).K$54DB).;)'TO8N@&_2\?A\CK%,^13/V&V$8QY"O=>?M@GR"
M]\CGK-EWN"2%:N21A50*9BS)5Y8D'+*!9#%&7!<!BJ=QE'BYDXW$N.2B$! U
M@8?M9%H7"(IG^!\!IW8$(;F4N^8BC\LM6$9N!=](#*ZN&A1/]C_"51MFKN2S
MR*+F!<<UIR&&5E<->E;9J-#F4AM(T7^)_/0NQA6'/O4IQE97#8HG^W(-0^C%
M3Z/@ H/>X!U&4A<*BF?V3S("I\RW,L,R<8M(/Z 7@V PQ(CJ$D'QO/X-"H3A
MF2U6:9$=$IQNI,*%VHJ67Q<''T_?"YF(",H65-)[B&\E6-+8S.(JK3QU'?#Q
MI#U7_"("]W#88/L.%II(Z+4_K]?-Z]>BUTIVU/+CR?I_9#.M"R!K!<1E6P'K
M=._CN7DI#/0<<DVH_^OJ'3DT)(TM48N2C4^HO LCHZ<.R9DBSRPI./G9NX36
MA.0P7;UE"L6NBX#?DK4/G.3N)=JR;,-/]L M0@_AXC;\TL3D'AU%[;$>^GCH
M'35)^!J4O,L^9&VU/RGO!T;FY>ET)0V<=<O++6>PS/8%>+Z6TKP-[(&W^G_%
MY#]02P,$%     @ <X!M6I^@&_"Q @  X@P   T   !X;"]S='EL97,N>&UL
MW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75E
MW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R
M5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#
M7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%
M8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE
M+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8
M Y?R 5KXK;J*W5<D].)3"6T@L-5)](1&,80)"L2_C!9B7X2]_:VPI!&/QGWL
M_&[TH'_OC./WEE>B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2S
MP:0<O(%;2AZY=>)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DM
MC)/Q]%P<T:L#.EL)7(0;^A7N5WGF0/:=D$[H43N*LN3ZQ3GUX1W;^PO\*KY?
M7_**==+M9G!#S_(77HI.Y?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D
M7O!9QP<<GB-WPQ-',)^ Q1' L#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$
MKQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3
M\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q
M;M@)QI$\QQ"8Q?B,9AE2G0P^\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X
M#SY['R73>RHY_U=3_ 102P,$%     @ <X!M6I>*NQS     $P(   L   !?
M<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^O
MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M!F_236P@R*2*Y U+2X<L-03&IAJ O<NF>3[+O,&@EXN1:T/9=1,92L88!.R
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M4$L! A0#%     @ <X!M6@=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !S@&U:P2?[]NT    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" !S@&U:F5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( '. ;5HY?/[R: 0  +L0   8
M      " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" !S@&U:GZ ;\+$"  #B#   #0              @ &J#   >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( '. ;5J7BKL<P    !,"   +              "
M 88/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( '. ;5H<.&7J/P$  #P"   /
M              "  6\0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !S
M@&U:)!Z;HJT   #X 0  &@              @ ';$0  >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !S@&U:99!YDAD!  #/ P  $P
M            @ ' $@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 )
+ #X"   *%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="atyr-20240314.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="atyr-20240314.htm">atyr-20240314.htm</File>
    <File>atyr-20240314.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "atyr-20240314.htm": {
   "nsprefix": "atyr",
   "nsuri": "http://www.atyrpharma.com/20240314",
   "dts": {
    "inline": {
     "local": [
      "atyr-20240314.htm"
     ]
    },
    "schema": {
     "local": [
      "atyr-20240314.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_85e8cb65-225c-451c-96f5-48835f1991fd",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atyr-20240314.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_85e8cb65-225c-451c-96f5-48835f1991fd",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atyr-20240314.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.atyrpharma.com/20240314/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-25-038703-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-038703-xbrl.zip
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M%HE:T'<<\RCB0_0AC&GLAS1"UZ->CV"8OH).HPA=B6H9NN(93^\X4XI&.SG
M V 29^\.)H9^KRM)>ML@KNLV!J+,05&H.?#2B(7CLN)1EM14U6H4'Z>*YC.+
MFD71?+)H.#6 R=)Z ^"8P]3XJ#Q _LLSQ<5GCV;CXH,GY:?F)[Z.BH:#>>T2
M,0R!<H'Q4?$XB2\ \VGHSZ[&\K21#WN\ 05Q7)0<CRH+9XT)9D :OW_Z>.UW
M>)?BQU-G_!'T,^XKM\E= SY 7<T8SR1+#(W8ST&U*#&J0/-A.E5:O.AU:-JE
MDGA%XZI.'CH8Y!@ZGZHR&LP#I!IY2N,L2* 509$"D$#I#M;)1#NS!_E<(YJ&
M50T3:]1(/T_GSM1MP->#]]^ADPZG#/ZBDSS,(_[>P;^>-(J?XF67YU3R+^9_
M]<.[=P>M),Z!J_$-8/  ^<73NX.<#_*&9(J&:+11MGKB)6R(LGP8\7<'/<J$
M3&DZO<%QEZ:W8=RD_3SY1]CM)2D@-#\^D'VR\&Y4A859+Z)#05,<OIZ$@Z9H
MF:?%SY Q'LN?#T2'0O;NX,,?Q E4C7H$&X9G8(.Y/O9L5<6^$9@.L1C7/1A_
M3+NB%QXVSV.8]+ %DTEIU(X9'_S*A^4$!_D5#V#J?S@F=WS/,K&FF3XV3.)C
MUPI,;#B.;@; .21@!^]5H%9==UU;/6E,#6WV2*'!P/5]@@-+AZ8\1X610LLV
MUS6BZ7I@.%,C/06IRH1D_1#1VQ>-$!54\^X R*P9A /.<$ CD WOY9\GHVY,
MPSKE 4]!0_#L_8F0$\U,LB6, $FYT13<_>X@ [Q&@D?ENTXJ!BC8!X^81AED
M#,A%-C_9IGS,DGXJGZ0<;):SE"!;%@]E52XQ.WH*F7@.0IXB.6P^DU=;[5^G
M\?BX\OO1J^G6>P"PA(V>0$JEN5!F[\64I2XS1O4>OHV'R>84'7T9/8\Z:4R!
M9@3',> :$\S2 )YZS%LE.^(\Z355Q0SCX[]!L@+A-[%^W UCW.%"/9;?>DD6
M"CD#/414Z/YC+QG@+/Q;<+27I- -AC>"27NC'@(8F2C"FT3MY27/%_T=RV\!
M[8;1L'D3=GDFS8JKI$OC44$OR?.D"V7%]#"-PMNX&?% B(F3K$?C43?WG3#G
M&-[XO-E+.;Y/:>_X4=_/=2>_?>%I+*8B)8V8_7W(\@YP1XY+(0?=_O@]L=3C
MDX;H'8#:FP!L[S%8R]&34><SX4"T!6-[#(HQI(O&%;.7(Y;TO8@O@I*?1$G:
M_%Z5_XX7P6S1N):'&9H UQ2@*H3*Q-1]Z)6G+YW\?4'R7A*Q26@XE4'CMXOV
MS?D9NKXYO3F_'D&FEB-] =Y>S-4U1]KU>>NWJ_9-^_P:G5Z<H?/?6[^<7OQ\
MCEJ?/WUJ7U^W/U_L,;E)3%8GC/Y#LPX4RI/X")TI+07<1=-P-X"]+<C/$@M"
MUC<-]8?CE12/M9[> :T#7GS(1N6D_RU'41DMR&$O&N9&F6!5&.V.0/OP^>H3
MFD7U*_1V,-N;<51J6RXXLYYJZMA0N8=A@@;6 N9JFL-UA[@O<UH>/*!1:$GZ
MH#4%L?2C2XI[[$[MHJZHO;19V^:M4-9\!<*F.@4&MM/5^<4-NCJ__'QULYNZ
M]EO$VV4_S?HTSE&>H&ONR\@\T5&2(F(>LK<H"5#>X>)3/PWS$'HY'_@=&M]R
ML3H@/A-7-[XV?+M?+;[EJ@M@[8J+<"PZ'#USFD: W1SQ.[&<D\K/G+UM+K(@
M%@UMC@7!7<\ES* X8(XO; ".7=,)<$"\P&.&[=E<K<J"N)2AM/,BP#8=%V7P
M!G>AEXZHAAD=XB&  O.XK@C\1%._ RQZ)!?!%E@?E>KW59FB.F]B:SK]2>CO
MM>3%0U>:\3(&"PAAA 4^MFSN8(,S"[N&JF';\56?>@'5/;8N@Q7+*5?\-LS$
M.E5^ 5\JY9N%DU\>M:<W_WN%+G\YO?IT>H3:%RUE1=;9E3!*=7'PP_,!!14O
MT"TT1#I&,Z(9RGK<%VLD#(4Q"O,,@5$ "B-]NP%3H+HI[:[CLZ."<9M+0(N$
M\)JSS:D7\5GT(I:W1S@5@Q/-PUQ$<1S18=(OBQ0]N8X"F"V+ V-$M)?Q9L9[
M- 5;9)H&9#6Y7 [=IZ.^[\(L],(()&]S5+\L!*78&%BR-]U2-.>'R56\<I;%
M,EYC3C6R>A7-5HBV>C53<:T7=.8JEK&HVDDC3Q_#KESME&0ZDYSN 3'82SG]
MTI3_8_%B!GBGUE7#^/B.IWGHTZ@D7WC]6(:(4C,(?'L*9K:=X&EZ$-C<QSP(
M/&Q8%*;/= W[/F.NIWF6[ZUMB!=V0COVDQ3<"IG)<IT#M;>2?IRGPU;"ILUR
MD5TCULYSWDN3.]%.=?;X<EX2C^@]3?EB&P&(C*U*' 6J9M'';'JPQ0+PQJ3J
MLI!<6<&^!#2[PS=4)XRINHN):;O8\"G%CFV8V-2H9FN:177?KX9O/H01A[X]
MGFZ5!U258-W6;6?/!'LFF,<$JFV[@:EB.] 9D'%@8<\/*+9U1[,-V_ LMO8Z
M4,$$-W30+O.R?*E 7H$C-!7KAF["G%=@B>>L$*W.5DAU#%>QG[N<\RH-#!''
M3O(.3]&?_33,6"@#W)-HJGSBBBUJO_+LP5T/)ZVMMWMA74]AK=63Q2:0N ++
MM9)N-\RR"0[;/-9>;[K"+$.%%MJS5SW9:\=56/OJ&IUW>U$RY.G7K[.FS3MT
MD2AO%TQZ+>FYY)S7)/\9N>1+V(4K1J>>,D,U3%8#!T.S+,9)X&*340L;KN-@
M1PU4'!#3TSSF$<.IR,L^92SE65;^^1C&G&R5_(G8+X.NDS2%YP3]F\J=C5<)
M9=O(,%MJB$=36G?./B=N>99F:I@;AHL-SS6PZVDF)J['B49UFU85%GF*,&VK
M"+ON0WM(5]4EG,'79B,] -B;!L$^=0'"FAI@U_4YMCE5-<VP5(]6M!A<HJ,%
M/S^G-\G]=N.VU]#16<AODYWB&9UXIFH'&G8-%F"# 6(<3?.Q9AN6R5R7NZ9=
M*7:D;_PYO4R3NU#LL-TF0%JGFXDGKJ;#=MERV!10-FTM[P%20X"LZGIN56V9
M+F&!YX,QP0G%AD]L[%)XM!RP_TS+44VMHO!R*1@ODRRGT?^%/;DDN4VQZ&I$
M(]6$E>TZ>P\[[I*7="+RH2Y3T)UACT;H?,#]OM@MC3X'X+_R;-UXT$Y"]#7#
M0:\27:V#^-[#XRO@G!?*(E!32.BIF=)FI!_@KTA$JWDNZ\;R/&N9A?J0,/WC
M]XY&[.,,Y3SBO0Y40K%<43@2ZW=17] QHJ"KP<AAO(D.%VS&6#3&.;GBFA9P
MF_@!%NXF-BS=PQY371P8FDHL#@85(^O:62(B< HSJ=*RJAHQCNF\W4;D8"OD
MOCY9>!ZW5(<P3%W;P ;U*/94R\-,<ZEG!\Q2?6]=LOB8@/"^%)1?;4)'U2"V
M=8(=W7%WFCQV=\-C=<"X2')TVNM%8#2 7MSQW1X3:];K;_?XD*1 S.A"[O=(
M4?E8>CR@D +4DAL_&;H644/TD69YN8_P6]SUL=\.5QEH*CW4JCJZ:76X_T5N
M?Z:]7IKTTE"DE'G) 'D\2NX%1XB/@E&0@W]%01@)>RW,P'B#)AAP2IZ@+.SV
MHYS&/.EGT1!E- ^S8"AKEA42#Z8N5[VST7[KB<U6?6@H130>CKX%202]BXHB
M.SX4^399<QT&K(&^>94$%CD2HT(1^GCB4UN&EMXA1%3UV2U":VT(6KAKYFF5
MQ1MT:KC3YA5.*)QLZLTUOTTX^JV-KH==T&QOCC(:9S@#8S&89V[[1">6Y9A8
M)28#+\S5P=Q6 \RHKUHVUW1JK[T,^)\TS %[(E.O'Y>I-MG3O3=>DD0>!3&3
M Y8W&0_\\7MP+8SC.BP)UD$B+7>\68%#H(1))*+>Q$D>5WV0.X9FELKCT0D>
MXN".0V*CUH<KI.FJ @77,N!>'OG==I1JKRWVVJ(F(F%=;4&I;CJ^Z6"+<0T;
M-E>QZ_L&MDW'(T0SJ.5IZVJ+:W!0?) 9\>TG("4P?Z.]JJB+.%HN'VJ,0-0M
M,?A43Q"#8J)-J(JI$Y[&BL)0E:+D7E?L=<5>5^R2KB"FP2S#I=@)A+3WB(8]
M K\"Q_-TSW(,G5KKZHK+E NO0ISN+T_M%/&/]',0\'2O,^HBEI8[$1"J^!.8
M7.AG$(-A[=![NYP&*<KN=<A>A^QUR"[I$-77/8>+_/3 <K%AJ 9V5>J#>O#%
M*0"F[QA!Q3JDG65]GNXU20V%TX8TB<ZQ(>YW6T:3E&6_84VRO>M=:G'\6VW6
MDR="J<4Z'4\YFZ+F\4G*TBXJU^V @IOS0"BG+NYEBG.A\W7]AV=6GK>6MUF8
M(%L\5J\>5HAN*IIEO^!4.DO15'/U>KJCF(M/Z=OJAN$2L.6M8>-<A<=ZK"R6
MCJX0&Q<L/\C,BED-E!]4VUQ:&T[G3\QJ=#2,HM6M[E_93LKOC;BQL3BMV^\@
M/Z)9MLCR6!>1>X2MA;"4RA3>PLP^7+PQ9(^NUT3717G4L60O/K(\08]#1_#F
M0=G7[D"'W1?$E66<SLEEM@S"?-?#EAZ X\#$;FMB6%AU/=LGCF7I]MKG$I1V
MX9!HGI34F_2MA)\,A'F=)_Z7(P16#[JC49^C_P:HJP3UQ,VGG>I.,-T=@?-J
MF<M+GT*_A_WKP/X&?+#%AS%8A)NF2ERL^SX%0>$1['"-8</3:$ MV]37/W%F
M)"A&P0UY;\*3V)900&N=?;RDSLL8_6L#VQI6< E;M!?F-$*?:/J%YSL:;JGN
M>K:=BK94'5QIQTP$"#GRALB7"=@P\"]@@7%YCN>CY.@P0S!D#M1Z*^SLVS2Y
MSSLBSM@3"=,T0XP'85S<4E$DQ:GFC#NM'JZRDE=?%<%(S</:DO=?*:LC:PU9
M62=TG<\!O=1IS^Y*<YXL;;UD60(D+.&N;F'3LN3:1("I:S"L.H&MZP8SF%71
MR4:CF?XL)]HJYKF9%8F7P&<#2QG?%B6W@V=$B=B/.U,NA4_V:W1 ZO"(^SE(
MG3B1X>!^QF4IF'BY+01*9J$,$??DY62"C&1?T5!T?A]"UX*-8I@(?$GY79A!
M/9!E-/9%%A?U?7%Y@BB<Y31F-&59L1^$S8M%ZX=T'(N>%&+*.EJ^\KTC4Y*C
M)$(6WA71+F$<WW(\'28&^A$%RH'_+</H@R;6CX.(#S +TP( (N[;[\;'+,QZ
M$1TVQ=<GIK$BC%TQMM)S+U[\V<_R,!B.ABFK8L#D<2\IL-A,>43%"2"3,=RQ
MC3V8,I]7VF2V< UGP2XS:=BSI \VT[JK2=7A>,9)#X# \G^![\XX@%).+XPC
MT.(8*#TMEP&F/P NBM<%><A("@W H6C2Z)X.LS*&/DDG4UZ6Q/($Y3RA@)<@
MNAYFZ>;Q-G<A"Q-3T1WSAVE'E>B*_OSZUL*;CI^!4,FJ5:\=5IB&T\YY%VF*
MJB%TQ;-^E,M-?Y]!#Y3+XB#-T8>QH&\EH'C$A[DVYN0N5E?1#;O<0CK&@JNX
MKOT8"Z9"5'LCJXQU4NISMR).0LA63&LCD%B3&*L&QN=8>-@3MX<>(7HS3-%E
MAX(->X3:L:^ 1Y7UP8*@8$R(@ZY WG$*Y@N-8[ WA+J=,$+2DGZ%\2*L"G%U
M*BHLG#/N<W&> ]*)[,M0T"D8.+WQ+M;IYL&/"_HPA:PC^A9.5B?TPARYKD*$
M$9-WPJR\E%;RA]QC.[K@ *J :\C!Q0/;+.4!_(Y]/I=?OD74[_G@42 PC O'
M35C&HVPC(*JQ<)X\@&>*& 6E 4%"68]+;G@@6Z#+K .NGS3[/8X8!V^"(7'(
MCP:P"R/.Y&]R/.88,-3!M.!2!8P-=6=&U$$T/BOR<"2X!3Q5R72'HE+9W63A
MLM>W1^/[4.[!G4!9W_L3^BSXBZ,HI#)#(N3E-G2:HZP8TQ%,*2TGE_5!@DR"
M[V&F4RPYR8MB0WPB'9IRR_O<?8EE%&9J6LG35+ CL3S'>_(J4CZ0LD3LK>>Y
M@"SX3M!Y>4.I/S6*8O3%()82$'L;9JX-XRHJ^:\'0T4>*BS2_$;$*IDF6\N[
MW,)4GCB;FSW?HAI16.6Q+^PM&B.K#J!8-'FR.7^FIOEHQ%+4%USB"C+J!?GT
M#A#7-G/15DZIGW]B\9P3=M"(K>8YY[6X3>=E&2LCT^0B459=5EX?K('\I^I+
MWTRXT^=MKGMT[<OI]IL [QG/_#3L/;Z?;P/959O>Q%,+<?+*)+V'S;=%-'OV
MW "D1;SAZ^+0.AP17@.04-1)12H"S8<IY@/7_8,HG;P[GY:"8#8MR;89]\MK
M7ILRK")6Q,IDON5!>RG#L5=%./8(,1G"F8X6C^%.OQK>?Z74A24OA#->G=(K
MAL_7P?YU)II6 M-%E_26H[:PX:DO[R4YHSE%\L+:0[$JPT145>28A+&,K+;E
M*CKZ_:>KCX@E?E]$\:J\58"XRAKAT)HM>N\34M9(2-$4[2'5?-V=J1M-;5B&
MK%>%16WOR]#VR3BKHU#ND*@3R3[-QOE6LSN>X5E=68UKB2($XN/],O8*4NS5
MH5/EREMUARBT?[XXO?GMZGQGKF!XE9P,2[&LS:1IU2PIXW(B9;G(J/ZK#Y92
ML:"\W"Z,HUFIV*P?#9%/^R)]>C*+"+KQP$T&2(@,@QB%N<CHZ- H$,D#HB'I
M3)<%1-9'7^0PR.9 NW62% # 7K#QXZN4O#5<-35515MX-MB,(\@477M!+5,Q
M%E;;G4!)#2AVS2 ]=".^O#O0#C832JH!B%ZVT":V(*/+7TZO/IT>H?9%:^;"
M\>Z0:AT04<<%I3U8OCZP[+ER3WY[L-0-++O#E3L-YCWU_31L;@8P\ZXFW'6
M-;(&^I\PBM G!?V4)I0%2?+L\2)[%MZS\!XLVP?+GDGWU+@'2\W!TNJ$/)C8
MF?XY"$*?I[O-JCL#_3U1U@ LVB[FQNZ9L7*J.Z,Y;\Y+C]T&(>X*H+;+GCL-
ME1TXXG*?5KE/J]RG52X_?7W[:94G#2]AP_??G30Z>3=Z__]02P,$%     @
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M '8$>B%  GFM1%>;#% Q!D)<#T'(G-"I^!J^')D%H;:! ?=E2%(7JAL5F60
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MWU3./S?8*QAC5? 396O(41-"YTF"B_+[J) %"P8+1K4%X[4-;RG<:7(K,95
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M#+-LNC*F,J9N$Z92EO9>97B9,94QM0I\R)C*F#I7<OC1&GN8[@ZFKCR%?..
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M3^^[)AS^_!\_O>]G@^CG_P]02P$"% ,4    " !S@&U:-ZFUA3D5  #WUP
M$0              @ $     871Y<BTR,#(T,#,Q-"YH=&U02P$"% ,4
M" !S@&U:5KC&*]<(  "C90  $0              @ %H%0  871Y<BTR,#(T
M,#,Q-"YX<V102P$"% ,4    " !S@&U:631"/;4I   ;Z ( #P
M    @ %N'@  871Y<BUE>#DY7S$N:'1M4$L%!@     #  , NP   %!(
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>atyr-20240314_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="atyr-20240314.xsd" xlink:type="simple"/>
    <context id="C_85e8cb65-225c-451c-96f5-48835f1991fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001339970</identifier>
        </entity>
        <period>
            <startDate>2024-03-14</startDate>
            <endDate>2024-03-14</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_18f02ab1-44b4-4d9c-b700-c4f5816de3be">0001339970</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_cb6f9cc1-f635-4b80-b71c-7e321233f48e">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_80a76908-b053-40eb-ace4-2fd9228e3819">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_e9b91d4a-fd8c-488e-958f-f1bfbd47b7e0">2025-03-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_f11d1dfc-67e8-4ed6-9402-78c0cabfa3bd">ATYR PHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_b23ff7ec-effb-46ad-bd32-ccdd9b2b6cb0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_a31dd039-1579-4caa-8745-52a27226a3cc">001-37378</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_a0779f50-7f3d-48f6-bcfa-73827474b6d9">20-3435077</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_266de1f9-5da6-4988-80f0-f15b2bdb148c">10240 Sorrento Valley Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_ce6b6252-e449-4b94-9b25-19be12a37acc">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_3f12a541-ca9c-420f-99ce-7ea022460bad">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_31b507f2-94df-4dce-822c-27465d99e957">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_591dfbc2-ee1a-4c17-9ac2-68f155680529">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_22fe71cf-65d9-463b-bd09-f42016ee8cd1">858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_bbe6081d-a974-4aba-b06b-d29ab7fd60cb">731-8389</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_c1316685-015d-4693-b00f-dac067e23a77">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_aa358c58-6de2-47e0-9cc4-758b1124a6b2">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_154d649a-8ff5-4b12-b1f5-f8bb3b6843a6">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_0c3b8edf-4f69-4404-90ac-22ca0775c84f">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_b641dc9b-63fe-4df2-9146-09b7c186637c">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:SecurityExchangeName
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_61e55019-3cca-4db1-8e2d-4b2afa67538c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_85e8cb65-225c-451c-96f5-48835f1991fd"
      id="F_8831e936-566f-4f6f-a94d-08f7334d4d6d">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
